Drug Abuse and Dependence
NPP 150 has a strong anabolic effect that stimulates the synthesis of proteins, as well as protein accumulation in the human muscle cell. This action is combined with mild androgenic properties facilitates the tissue regeneration of the athlete, and assists in maintaining muscle mass during a dieting period. It turned out that NPP 150 accumulates a lower quantity of water in the human body than Deca. Therefore, NPP is much more appropriate for preparation for a sport event or competition while, on the other hand, Deca has the advantage of accumulating muscular strength and mass. The growth in this case is slower and slighter than with Deca but it is of higher quality and is able to retain much of it after the end of intake. Efficient for this combination is the stack of 50 mg NPP every two days, 50 mg test prop every second day, plus 20 mg Winstrol tablet a day.
Hypercalcemia may develop both spontaneously and as a result of androgen therapy in women with disseminated breast carcinoma. If it develops while on this agent, the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or hepatic disease. Cholestatic jaundice is associated with therapeutic use of anabolic and androgenic steroids. Edema may occur occasionally with or without congestive heart failure. Concomitant administration of adrenal steroids or ACTH may add to the edema. In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months. This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.